Stock ELAB ELEVAI LABS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Elevai Labs Inc.

Equities

ELAB

US28622K1043

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:00 23/05/2024 am IST 		5-day change 1st Jan Change
0.665 USD -1.48% Intraday chart for Elevai Labs Inc. +5.56% -63.63%
19/05 Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
02/05 Elevai Biosciences Inc. Highlights Preclinical Data Showing Potential of In-Licensed Asset ?EL-22? for The Treatment of Obesity CI

Valuation

Fiscal Period: December 2023
Capitalization 1 31.68
Enterprise Value (EV) 1 28.57
P/E ratio -4.57 x
Yield -
Capitalization / Revenue 1,84,99,413 x
EV / Revenue 1,66,79,740 x
EV / EBITDA -78,10,319 x
EV / FCF -1,22,14,575 x
FCF Yield -0%
Price to Book 8.28 x
Nbr of stocks (in thousands) 17,330
Reference price 2 1.828
Announcement Date 29/03/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales - 0.000827 0.7663 1.713
EBITDA - -0.7823 -1.708 -3.657
EBIT 1 -0.2218 -0.7851 -1.714 -3.669
Operating Margin - -94,928.9% -223.72% -214.24%
Earnings before Tax (EBT) 1 -0.2229 -0.7847 -1.8 -4.302
Net income 1 -0.2229 -0.7847 -1.8 -4.302
Net margin - -94,889.84% -234.94% -251.17%
EPS 2 -0.0505 -0.0829 -0.1889 -0.4003
Free Cash Flow - -0.4 -0.8399 -2.339
FCF margin - -48,369.89% -109.61% -136.56%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 14/02/23 14/02/23 29/09/23 29/03/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 0.01 - - -
Net Cash position 1 - 0.41 0.87 3.12
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -0.4 -0.84 -2.34
ROE (net income / shareholders' equity) - -368% -228% -174%
ROA (Net income/ Total Assets) - -144% -83.8% -64.8%
Assets 1 - 0.5464 2.149 6.642
Book Value Per Share 2 -0.0100 0.0500 0.1200 0.2200
Cash Flow per Share 2 0 0.0400 0.1200 0.1900
Capex - 0.03 0.04 0.01
Capex / Sales - 3,927.57% 4.64% 0.65%
Announcement Date 14/02/23 14/02/23 29/09/23 29/03/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ELEVAI LABS INC. Stock Elevai Labs Inc.
-63.63% 1.15Cr
MODERNA, INC. Stock Moderna, Inc.
+64.23% 6.26TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.31% 4.12TCr
LONZA GROUP AG Stock Lonza Group AG
+44.98% 4.03TCr
CELLTRION, INC. Stock Celltrion, Inc.
-8.29% 2.79TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.97% 2.62TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.16% 1.91TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.54% 1.31TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.17% 1.21TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.72% 1.23TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ELAB Stock
  4. Financials Elevai Labs Inc.